FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 353:2503-2505 December 8, 2005 Number 23 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by McDonald, L. C. Related Article by Loo, V. G. PubMed Citation

Recent experience with influenza, the severe acute respiratory syndrome (also known as SARS), avian influenza, and community-acquired methicillin-resistant Staphylococcus aureus has demonstrated how old pathogens can emerge with increased virulence and challenge scientists to explain their rebirth, clinicians to care for patients, and infection-control personnel to prevent their spread. Clostridium difficile appears to illustrate these challenges. It already has some distinctive features: it causes disease almost exclusively in the presence of exposure to antibiotics, it is the only anaerobe that poses a nosocomial risk, and it produces toxin in vivo only in the colon.

About 3 percent of healthy adults . . . [Full Text of this Article]

Source Information

From the Department of Medicine, Johns Hopkins University School of Medicine, Baltimore.

This article has been cited by other articles:

• Giesemann, T., Egerer, M., Jank, T., Aktories, K. (2008). Processing of Clostridium difficile toxins. J Med Microbiol 57: 690-696 [Abstract] [Full Text]  
• Monaghan, T, Boswell, T, Mahida, Y R (2008). Recent advances in Clostridium difficile-associated disease. Gut 57: 850-860 [Abstract] [Full Text]  
• Emerson, C. R. (2007). Clostridium difficile Associated Diarrhea, an Emerging Epidemic: Therapeutic Options. Journal of Pharmacy Practice 20: 347-353 [Abstract]  
• Kenneally, C., Rosini, J. M., Skrupky, L. P., Doherty, J. A., Hollands, J. M., Martinez, E., McKenzie, W., Murphy, T., Smith, J. R., Micek, S. T., Kollef, M. H. (2007). Analysis of 30-Day Mortality for Clostridium difficile-Associated Disease in the ICU Setting. Chest 132: 418-424 [Abstract] [Full Text]  
• Karpa, K. D. (2007). Probiotics for Clostridium difficile Diarrhea: Putting It into Perspective. The Annals of Pharmacotherapy 41: 1284-1287 [Abstract] [Full Text]  
• Ghose, C., Kalsy, A., Sheikh, A., Rollenhagen, J., John, M., Young, J., Rollins, S. M., Qadri, F., Calderwood, S. B., Kelly, C. P., Ryan, E. T. (2007). Transcutaneous Immunization with Clostridium difficile Toxoid A Induces Systemic and Mucosal Immune Responses and Toxin A-Neutralizing Antibodies in Mice. Infect. Immun. 75: 2826-2832 [Abstract] [Full Text]  
• Surowiec, D., Kuyumjian, A. G, Wynd, M. A, Cicogna, C. E (2006). Past, Present, and Future Therapies for Clostridium difficile-Associated Disease. The Annals of Pharmacotherapy 40: 2155-2163 [Abstract] [Full Text]  
• Bourgault, A.-M., Lamothe, F., Loo, V. G., Poirier, L., the CDAD-CSI Study Group, (2006). In Vitro Susceptibility of Clostridium difficile Clinical Isolates from a Multi-Institutional Outbreak in Southern Quebec, Canada.. Antimicrob. Agents Chemother. 50: 3473-3475 [Abstract] [Full Text]  
• Rathore, M. H., Barton, L. L. (2006). Clostridium difficile: Old Scourge Becomes Far Worse. AAP Grand Rounds 15: 15-16 [Full Text]  
• (2005). Further Insights into Worsening Clostridium difficile Disease. JWatch Infect. Diseases 2005: 1-1 [Full Text]  
• (2005). A New, More Virulent Strain of C. difficile. JWatch General 2005: 1-1 [Full Text]